Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.

This review discusses the potential of various Indian herbal medicines in treating cognitive impairment related to Alzheimer's disease but reports no new clinical findings; it highlights the need for further research.

Monitoring for adverse effects in clinical treatments is crucial.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

This study observed that valproic acid treatment led to a significant reduction in aggressive and impulsive behaviors among patients with acquired brain injury, with varying effects based on cognitive impairment degree; the treatment was generally well-tolerated, though some patients experienced temporary side effects.

This study suggests that a newly discovered protein, AMY117, found in Alzheimer's disease brain lesions may be crucial in the disease's development and progression.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This study found that microbial transformation of dihydrotestosterone with two types of fungi produced eight metabolites, among which metabolites 5–7 were significant inhibitors of butyrylcholinesterase, suggesting potential in Alzheimer's disease management.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This study suggests that apoE4 may contribute to cognitive decline by reducing androgen receptor levels in the brain, but androgen treatment improved memory deficits in female mice expressing human apoE4.

In this study, repeated finasteride administration was associated with decreased social interaction and cognitive deficits in male rats, potentially linked to changes in cholinergic system activity.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This review discusses the potential of using triads of repositioned medicines targeting multiple pathogenic mechanisms to prevent or delay retina degeneration, but reports no new results.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This study suggests that finasteride may inhibit the enzyme phenylethanolamine N-methyltransferase, which could contribute to its sexual and psychological side effects.

This study found that in sleep-deprived rats, increased 5α-reductase expression and activity in the prefrontal cortex contributed to psychosis- and mania-like symptoms, which finasteride ameliorated in a dose-dependent manner.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

In this rodent study, researchers found that the drug finasteride may reduce anxiety and depression-like behaviors in a model of aging, despite inducing metabolic disturbances and depressive-like behaviors in young rats, suggesting potential considerations for its use in elderly populations.

Finasteride improved reflexes and motor activity in rats with liver-related brain issues.